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            Amendments from Version 2
We have addressed the reviewers’ comments regarding overfitting by 
1) deriving and validation biochemically inspired machine learning 
models using the METABRIC Validation patient dataset independently 
of the Discovery data and 2) assessing the accuracy of the Discovery 
dataset-based models with patient data derived from an independent 
source (reference 5). In addition, we have stratified the patients by 
breast cancer subtype and evaluated each subtype with the combined 
Discovery+Validation dataset-based models using all of the feature 




Current pharmacogenetic analysis of chemotherapy makes quali-
tative decisions about drug efficacy in patients (determination of 
good, intermediate or poor metabolizer phenotypes) based on vari-
ants present in genes involved in the transport, biotransformation, 
or disposition of a drug. We have applied a supervised machine 
learning (ML) approach to derive accurate gene signatures, based 
on the biochemically-guided response to chemotherapies with 
breast cancer cell lines1, which show variable responses to growth 
inhibition by paclitaxel and gemcitabine therapies2,3. We analyzed 
stable4 and linked unstable genes in pathways that determine their 
disposition. This involved investigating the correspondence 
between 50% growth inhibitory concentrations (GI50) of paclitaxel 
and gemcitabine and gene copy number, mutation, and expression 
first in breast cancer cell lines and then in patients1. Genes encoding 
direct targets of these drugs, metabolizing enzymes, transporters, 
and those previously associated with chemo-resistance to pacli-
taxel (n=31 genes) were then pruned by multiple factor analysis 
(MFA), which indicated that expression levels of genes ABCC10, 
BCL2, BCL2L1, BIRC5, BMF, FGF2, FN1, MAP4, MAPT, 
NKFB2, SLCO1B3, TLR6, TMEM243, TWIST1, and CSAG2 could 
predict sensitivity in breast cancer cell lines with 84% accuracy. 
The cell line-based paclitaxel-gene signature predicted sensitiv-
ity in 84% of patients with no or minimal residual disease (n=56; 
data from 5). The present study derives related gene signatures 
with ML approaches that predict outcome of hormone- and 
chemotherapies in the large METABRIC breast cancer cohort6.
Methods
SVM (Support Vector Machine) learning: Previously, paclitaxel- 
related response genes were identified from peer-reviewed 
literature, and their expression and copy number in breast cancer 
cell lines were analyzed by multiple factor analysis of GI50 values 
of these lines2 (Figure 1). Given the expression levels of each gene, 
a SVM is evaluated on patients by classifying those with shorter 
survival time as resistant and longer survival as sensitive to hormone 
and/or chemotherapy using paclitaxel, tamoxifen, methotrexate, 
5-fluorouracil, epirubicin, and doxorubicin. The SVM was trained 
using the function fitcsvm in MATLAB R2014a7 and tested with 
either leave-one-out or 9 fold cross-validation (indicated in 
Table 1). The Gaussian kernel was used for this study, unlike 
Dorman et al.1 which used the linear kernel. The SVM requires 
selection of two different parameters, C (misclassification cost) 
and sigma (which controls the flexibility and smoothness of 
Gaussians)8; these parameters determine how strictly the SVM 
learns the training set, and hence if not selected properly, 
can lead to overfitting. A grid search evaluates a wide range of 
combinations of these values by parallelization. A Gaussian 
kernel selects the C and sigma combination that lead to the low-
est cross-validation misclassification rate. A backwards feature 
selection (greedy) algorithm was designed and implemented in 
MATLAB in which one gene of the set is left out in a reduced gene 
set and the classification is then assessed; genes that maintain or 
lower the misclassification rate are kept in the signature. The pro-
cedure is repeated until the subset with the lowest misclassifica-
tion rate is selected as the optimal subset of genes. These SVMs 
were then assessed for their ability to predict patient outcomes 
based on available metadata (see Figure 1 and reference 1). Inter-
active prediction using normalized expression values as input is 
available at http://chemotherapy.cytognomix.com.
RF (Random Forest) learning: RF was trained using the WEKA 
3.79 data mining tool. This classifier uses multiple random trees for 
classification, which are combined via a voting scheme to make 
a decision on the given input gene set. A grid search was used to 
optimize the maximum number of randomly selected genes for 
each tree in RF, where k (maximum number of selected genes 
for each tree) was set from 1 to 19. Figure 2 depicts the therapy 
outcome prediction  process of a given patient using a RF consist-
ing of a series of decision trees derived from different subsets of 
paclitaxel-related genes.
Augmented Gene Selection: The most relevant genes (features) 
for therapy outcome prediction were found using the Minimum 
Redundancy and Maximum Relevance (mRMR) approach10. 
mRMR is a wrapper approach that incrementally selects 
genes by maximizing the average mutual information between 





max ( , ) ( , )
i i j
i i js
f S f f S






where fi corresponds to a feature in gene set S, I(fi,C) is the mutual 
information between fi and class C, and I(fi,fj) is the mutual informa-
tion between features fi and fj.
For this experiment, we used a 26-gene signature (genes ABCB1, 
ABCB11, ABCC1, ABCC10, BAD, BBC3, BCL2, BCL2L1, BMF, 
CYP2C8, CYP3A4, MAP2, MAP4, MAPT, NR1I2, SLCO1B3, 
TUBB1, TUBB4A, TUBB4B, FGF2, FN1, GBP1, NFKB2, OPRK1, 
TLR6, and TWIST1) as the base feature set. These genes were 
selected (in Dorman et al.1) based either on their known involvement 
in paclitaxel metabolism, or evidence that their expression levels 
and/or copy numbers correlate with paclitaxel GI50 values. mRMR 
and SVM were combined to obtain a subset of genes that can accu-
rately predict patient survival outcomes; here, we considered 3, 
4 and 5 years as survival thresholds for breast cancer patients.
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Performance was evaluated with several metrics. WEKA deter-
mined accuracy (ACC), the weighted average of precision and 
F-measure, the Matthews Correlation Coefficient (MCC) and the 





The predicted and expected response to treatment for each 
individual METABRIC patient for each analyses listed in Table 1, 
Table 2 and Table 3 are indexed. Patients sensitive to treatment are 
labeled with ‘0’ while resistant patients are labeled ‘1’.
The performances of several ML techniques have been compared 
such that they distinguish paclitaxel sensitivity and resistance in 
METABRIC patients using its tumour gene expression datasets. We 
used mRMR to generate gene signatures and determine which genes 
are important for treatment response in METABRIC patients. The 
paclitaxel models are more accurate for prediction of outcomes in 
patients receiving HT and/or CT compared to other patient groups.
SVMs and RF were trained using expression of genes associated 
with paclitaxel response, mechanism of action and stable genes 
in the biological pathways of these targets (Figure 3). Pair-wise 
comparisons of these genes with those from MammaPrint and 
Oncotype Dx (other genomic classifiers for breast cancer) find that 
these signatures are nearly independent of each other, with only 
a single gene overlap. The distinct differences of these signatures 
are due to their methodology of derivation, based on different 
principles and for different purposes (i.e. drug response for a spe-
cific reagent). SVM models for drugs used to treat these patients 
were derived by backwards feature selection on patient subsets 
stratified by treatment or outcome (Table 1). The highest SVM 
accuracy was found for the paclitaxel signature in patients treated 
with HT and/or adjuvant chemotherapy (78.6%). Since some 
CT patients were also treated with tamoxifen, methotraxate, 
epirubicin, doxorubicin and 5-fluorouracil, we also evaluated 
the performance of models developed for these drugs using the 
same algorithm. These gene signatures also had acceptable 
performance (accuracies between 71–76%; AUCs between 0.686 
– 0.766). Leave-one-out validation (CT and HT, no treatment, 
and deceased patients) exhibited higher model performance than 
9-fold crossvalidation (CT and/or HT, including patients treated 
with radiation).
The RF classifier was used to predict paclitaxel therapy outcome 
for patients that underwent CT and/or HT (Table 2). The best 
performance achieved with RF showed an 85.5% overall accuracy 
using a 3-year survival threshold for distinguishing therapeutic 
resistance vs. sensitivity for those patients that underwent HT.
The best overall accuracy and AUC (sensitivity and specificity) for 
CT/HT patients using mRMR feature selection for SVM predict-
ing outcome of paclitaxel therapy was obtained for CT patients 
with 4-year survival (Table 3). Outcomes for HT patients with 
Figure  1. Biochemically-inspired SVM gene signature derivation workflow. The initial set of genes is carefully selected through the 
understanding of the drug and the pathways associated with it. A multiple factor analysis of the GI50 values of a training set of breast cancer 
cell lines and the corresponding expression levels of each gene in the initial set reduces the list of genes.
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Paclitaxel: ABCC1, ABCC10, BAD, 
BIRC5, FN1, GBP1, MAPT, SLCO1B3, 
TMEM243, TUBB3, TUBB4B 
(C=10000, σ=10) 
78.6 0.787 0.782 0.559 0.814
Tamoxifen: ABCC2, ALB, CCNA2, 
E2F7, FLAD1, FMO1, NCOA2, NR1I2, 
PIAS4, SULT1E1 (C=100000, σ=100) 
76.2 0.761 0.760 0.510 0.701
Methotrexate: ABCC2, ABCG2, 
CDK2, DHFRL1 (C=10, σ=1) 71.4 0.712 0.711 0.410 0.766
Epirubicin: ABCB1, CDA, CYP1B1, 
ERBB3, ERCC1, MTHFR, PON1, 
SEMA4D, TFDP2 (C=1000, σ=10) 
72.6 0.725 0.723 0.434 0.686
Doxorubicin: ABCC2, ABCD3, CBR1, 
FTH1, GPX1, NCF4, RAC2, TXNRD1 
(C=100000, σ=100) 
75.0 0.749 0.750 0.488 0.701
5-Fluorouracil: ABCB1, ABCC3, 
MTHFR, TP53 (C=10000, σ=100) 71.4 0.714 0.714 0.417 0.718
CT and/or 
HT3,4,5,6 735
Paclitaxel: BAD, BCAP29, BCL2, 
BMF, CNGA3, CYP2C8, CYP3A4, 
FGF2, FN1, NFKB2, NR1I2, OPRK1, 
SLCO1B3, TLR6, TUBB1, TUBB3, 
TUBB4A, TUBB4B, TWIST1 
(C=10000, σ=100) 






Paclitaxel: ABCB11, BAD, BBC3, 
BCL2, BCL2L1, BIRC5, CYP2C8, 
FGF2, FN1, GBP1, MAPT, NFKB2, 
OPRK1, SLCO1B3, TMEM243 
(C=100, σ=10)
75.3 0.752 0.752 0.505 0.763
No 
treatment3 304
Paclitaxel: ABCB1, ABCB11, BBC3, 
BCL2L1, BMF, CYP3A4, FGF2, 
GBP1, MAP4, MAPT, NR1I2, OPRK1, 
SLCO1B3, TUBB4A, TUBB4B, 
TWIST2 (C=100, σ=10)
73.4 0.734 0.733 0.467 0.769
Initial gene sets preceding feature selection: Paclitaxel - ABCB1, ABCB11, ABCC1, ABCC10, BAD, BBC3, BCAP29, 
BCL2, BCL2L1, BIRC5, BMF, CNGA3, CYP2C8, CYP3A4, FGF2, FN1, GBP1, MAP2, MAP4, MAPT, NFKB2, NR1I2, 
OPRK1, SLCO1B3, TLR6, TUBB1, TWIST1. Tamoxifen - ABCB1, ABCC2, ALB, C10ORF11, CCNA2, CYP3A4, E2F7, 
F5, FLAD1, FMO1, IGF1, IGFBP3, IRS2, NCOA2, NR1H4, NR1I2, PIAS4, PPARA, PROC, RXRA, SMARCD3, SULT1B1, 
SULT1E1, SULT2A1. Methotrexate - ABCB1, ABCC2, ABCG2, CDK18, CDK2, CDK6, CDK8, CENPA, DHFRL1. Epirubicin 
- ABCB1, CDA, CYP1B1, ERBB3, ERCC1, GSTP1, MTHFR, NOS3, ODC1, PON1, RAD50, SEMA4D, TFDP2. Doxorubicin 
- ABCB1, ABCC2, ABCD3, AKR1B1, AKR1C1, CBR1, CYBA, FTH1, FTL, GPX1, MT2A, NCF4, RAC2, SLC22A16, 
TXNRD1. 5-Fluorouracil - ABCB1, ABCC3, CFLAR, IL6, MTHFR, TP53, UCK2. 1MCC: Matthews Correlation Coefficient. 
2AUC: Area under receiver operating curve. 3 Surviving patients; 4 Analysis included patients in the METABRIC 
‘discovery’ dataset only; 5 SVMs tested with 9 fold cross-validation, all others tested with leave-one-out cross-validation; 
6 Includes all patients treated with HT,CT, combination CT/HT, either with or without combination radiotherapy; 7 Median 
time after treatment until death (> 4.4 years) was used to distinguish favorable outcome, ie. sensitivity to therapy.
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Figure 2. RF decision tree diagram depicts the therapy outcome prediction process of a given patient, using a RF consisting of k 
decision trees. Several DTs are built using different subsets of paclitaxel-related genes. The process starts from the root of each tree and 
if the expression of the gene corresponding to that node is greater than a specific value, the process continues through the right branch, 
otherwise it continues through the left branch until it reaches a leaf node; that leaf represents the prediction of the tree for that specific input. 




























































7 56.6 0.510 0.524 -0.095 0.441
4 7 69.8 0.698 0.698 0.396 0.700








19 85.5 0.731 0.788 0.000 0.606
4 9 78.6 0.715 0.706 0.069 0.559






9 82.7 0.685 0.749 0.000 0.506
4 19 73.6 0.647 0.648 0.039 0.527
5 7 65.3 0.602 0.593 0.086 0.588
1MCC: Matthews Correlation Coefficient. 2AUC: Area under receiver operating 
curve; both Discovery and Validation patient datasets analyzed. RF predictions 
done using a gene panel consisting of 19 genes (ABCB1, ABCB11, ABCC1, 
ABCC10, BAD, BBC3, BCL2, BCL2L1, BMF, CYP2C8, CYP3A4, MAP2, MAP4, 
MAPT, NR1I2, SLCO1B3, TUBB1, TUBB4A, TUBB4B). Page 6 of 25
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Table 3. Results of mRMR feature selection for an SVM for predicting outcome of paclitaxel therapy.
Data CT1 HT CT+HT
Survival years 
(as threshold) 3 4 5 3 4 5 3 4 5
# patients2 53 420 504
Accuracy (TP) 
(%) 81.1 81.1 84.9 85.7 79.5 72.9 83.1 74.8 67.9
Precision 0.809 0.813 0.852 0.878 0.765 0.692 0.795 0.703 0.662
F-Measure 0.809 0.811 0.845 0.794 0.726 0.663 0.772 0.672 0.666
MCC 0.582 0.625 0.675 0.119 0.17 0.173 0.161 0.137 0.238
AUC 0.783 0.812 0.82 0.508 0.533 0.548 0.53 0.531 0.61
SVM Par. 
(gamma) 0.0 0.5 1.0 1.0 0.75 1.5 0.75 0.5 1.0
SVM Par. 


































































































1For patients treated with CT with ≥4 Yr survival and CT+ HT for ≥ 5 Yr, the cost for the mRMR model was set to 64. Of those treated with CT for 
≥ 4 Yr, genes were selected using a greedy, stepwise forward search, while in other cases, greedy stepwise backward search was used. Also, 
gamma = 0 in all cases. 2Predicted responses for individual METABRIC patients are provided in Dataset 1.
3-year survival were predicted with 85.7% accuracy; however, the 
specificity was lower in this group. SVM combined with mRMR 
further improved accuracy of feature selection and prediction 
of response to hormone and/or chemotherapy based on survival 
time than either SVM or RF alone. Predicted treatment responses 
for individual METABRIC patients using the described ML 
techniques are indicated in Dataset 1.
Tumor co-variate information was provided by METABRIC, 
which included Estrogen receptors (ER), Progesterone Recep-
tor (PR), HER2, Lymph Node (LN) and PAM50 subtypes. 
To assess model co-variate accuracy, predictions described in 
Table 1–Table 3 were broken down by subtype (available in 
Supplementary file 1). Subtypes with <20 individuals for a 
particular treatment combination were not analyzed. The deviation 
in classification accuracy between subtypes was mostly consistent 
with the average. One exception involved the RF and mRMR 
analyses, which was 8.3 to 23.0% below the average for (ER)-
negative, (HER2)-positive and basal subtypes in patients treated 
with HT. However, this deviation was not observed for CT-treated 
patients with the (ER)-negative subtype, which was consistent 
with the fact that CT response was derived from the paclitaxel 
gene set. (ER)-negative patients primarily received CT6. Further, 
the accuracy of the SVM models tested with CT and HT-treated 
patients was significantly higher for (HER2)-positive patients 
(26 correct, 3 misclassified; 90% accurate) compared to (HER2)- 
negative patients (40 correct, 15 misclassified; 73% accurate). 
MAPT expression (present in reduced ‘CT and HT’ paclitaxel 
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7 61.1 0.617 0.612 0.224 0.444
4 7 66.7 0.643 0.646 0.189 0.715








19 77.0 0.780 0.775 0.018 0.524
4 9 79.1 0.733 0.710 0.084 0.527






9 80.2 0.677 0.734 -0.07 0.389
4 19 54.8 0.554 0.551 -0.143 0.395
5 7 60.5 0.567 0.579 0.016 0.479
Paclitaxel gene panel consisted of 19 genes (ABCB1, ABCB11, ABCC1, ABCC10, BAD, BBC3, BCL2, BCL2L1, BMF, CYP2C8, 
CYP3A4, MAP2, MAP4, MAPT, NR1I2, SLCO1B3, TUBB1, TUBB4A, TUBB4B).
Figure 3. Schematic elements of gene expression changes associated with response to paclitaxel. Red boxes indicate genes with a 
positive correlation between gene expression or copy number, and resistance using multiple factor analysis. Blue demonstrates a negative 
correlation. Genes outlined in dark grey are those in a previously published paclitaxel SVM model (reproduced from reference 1 with 
permission).
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Table 5. Results of mRMR feature selection for an SVM for predicting outcome of the paclitaxel signature for 
the METABRIC Discovery patient set.




3 4 5 3 4 5 3 4 5
# patients 22 185 221
Accuracy 
(TP) (%) 57.14 57.14 85.7 81.8 70.9 63.6 71.2 69.7 71.2
Precision 0.595 0.686 0.735 0.726 0.670 0.532 0.647 0.629 0.693
F-Measure 0.571 0.623 0.791 0.769 0.686 0.562 0.668 0.628 0.666
MCC 0.167 -0.258 0.000 -0.080 0.032 -0.075 0.035 0.071 0.245
AUC 0.583 0.333 0.500 0.479 0.514 0.477 0.513 0.521 0.586
SVM Par. 
(gamma) 0.0 0.5 1.0 1.0 0.75 1.5 0.75 0.5 1.0
SVM Par. 






























































































































1For patients treated with CT with ≥4 Yr survival and CT+ HT for ≥ 5 Yr, the cost for the mRMR model was set to 64. Of those treated 
with CT for ≥ 4 Yr, genes were selected using a greedy, stepwise forward search, while in other cases, greedy stepwise backward 
search was used. Also, gamma = 0 in all cases.
Table 6. Comparison between our mRMR+SVM method and K-TSP method on Discovery patient set of 
the METABRIC data.
Data CT HT CT+HT
Survival years 3 4 5 3 4 5 3 4 5
# patients 22 185 221
mRMR+SVM Accuracy (%) 57.14 57.14 85.7 81.8 70.9 63.6 71.21 69.70 71.21
K-TSP12 Accuracy (%) 57.14 28.57 28.57 80.91 68.18 69.19 71.21 54.55 53.03
The performances of several ML techniques have been compared such that they distinguish paclitaxel sensitivity and 
resistance in METABRIC patients using its tumour gene expression datasets. We used mRMR to generate gene signatures 
and determine which genes are important for treatment response in METABRIC patients. The paclitaxel models are more 
accurate for prediction of outcomes in patients receiving HT and/or CT compared to other patient groups.
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model; Table 1) has been shown to segregate well with PAM50 
luminal and basal subtypes1. When analyzing METABRIC patients, 
however, the accuracy of these two subtypes are nearly identi-
cal to the average (78.6%, where basal and luminal classification 
accuracy is 76.7% [n=30] and 76.2% [n=21], respectively).
We assessed the separate Discovery and Validation datasets, 
respectively, as training and test sets and repeated the previous 
experiments. In this scenario, the performance of the model was 
poor (slightly better than random). This occurred because the gene 
expression distributions of many of the paclitaxel-related genes 
in our signature were not reproducible between these two sets 
(based on Wilcoxon rank sum test, Kruskal-Wallis test and t-tests; 
Supplementary file 2). Cross-study validation allows for the com-
parison of classification accuracy between the generated gene 
signatures. The observed heterogeneity in gene expression high-
lights one of the many challenges of cross-validation of gene 
signatures between these data from the same study exhibit drastic 
differences (for example, BCL2L1; Supplementary file 2). Fur-
thermore, these gene expression differences also affect the per-
formance of these methods when these datasets were combined 
(compare Table 2 and Table 4 for RF; Table 3 and Table 5 for 
mRMR). We considered the possibility that the Discovery model 
might be subject to overfitting. We therefore performed cross-study 
validation of the Discovery set-signature with an independently-
derived dataset (319 invasive breast cancer patients treated with 
paclitaxel and anthracycline chemotherapy5). The mRMR+SVM 
CT-models performed well (4-year threshold model had an overall 
accuracy of 68.7%; 3-year threshold model exhibited lower overall 
accuracy [52%], but was significantly better at predicting patients 
in remission [74.2%]).
To evaluate the paclitaxel models without relying on the Validation 
dataset, the Discovery set was split into two distinct parts, consist-
ing of 70% of the patient samples randomly selected for training, 
and a different set of 30% of samples for testing. This procedure 
was repeated 100 times using different combinations of training 
and test samples, and the median performance of these runs is 
reported (Table 4 and Table 5). We also compared the perform-
ance of our mRMR+SVM model with the K-TSP model12 (Table 6). 
In most cases, our method outperformed K-TSP, based on its 
accuracy in classifying new patients. Starting with the same set of 
Discovery genes, we also trained a separate model using the Valida-
tion data, and tested this data by 70/30% cross-validation (accuracy 
for RF: 56–67% [CT], 67–83% [HT], 56–81% [CT-HT]; accuracy 
for mRMR: 33–56% [CT], 70–84% [HT], 64–82% [CT-HT]). 
In addition, we evaluated the performance of the model derived 
from the Discovery set on a different set of patients treated with 
paclitaxel5. These results suggest that the aforementioned issue 
with Discovery training and Validation testing was primarily due to 
a batch effect, rather than to overfitting.
While not a replication study sensu stricto, the initial paclitaxel 
gene set used for feature selection was the same as in our previous 
study1. Predictions for the METABRIC patient cohort, which was 
independent of the previous validation set5 used in Dorman et al.1, 
of the either same (SVM) or different ML methods (RF and SVM 
with mRMR) exhibited comparable or better accuracies than our 
previous gene signature1.
These techniques are powerful tools which can be used to 
identify genes that may be involved in drug resistance, as well as 
predict patient survival after treatment. Future efforts to expand 
these models to other drugs may assist in suggesting preferred 
treatments in specific patients, with the potential impact of 
improving efficacy and reducing duration of therapy.
Conclusion
In this study we used METABRIC dataset to predict outcome for 
different survival times in patients receiving hormone (HT) and, 
in some cases, chemotherapy (CT) agents. We used published lit-
erature and various machine learning methods in order to identify 
optimal subsets of genes from a biologically-relevant initial gene 
set that can accurately predict therapeutic response of patients 
who have received chemotherapy, hormone therapy or a combi-
nation of both treatments. The SVM methodology has been pre-
viously shown to outperform randomized gene sets1. The predic-
tions made by our method are based on the level of an individual 
drug. Genomic information has been shown to correlate with 
tumor therapy response in previous studies5,13–17. From these stud-
ies, analytical methods have been used to develop gene signatures 
for chemotherapy resistance prediction5, subtypes (PAM50), and 
metastatic risk stratification (Oncotype DX™, MammaPrint®). We 
also examined the method exhibiting the best performance in the 
Sage Bionetworks / DREAM Breast Cancer Prognosis Challenge18, 
which was also phenotype-based, however it produces outcome 
signatures based on molecular processes rather than the cancer 
drugs themselves. While interesting and informative, the results 
cannot be directly compared. Our approach may be useful for 
selecting specific therapies in patients that would be expected to 
produce a favorable response.
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“Unlike Mammaprint and Oncotype Dx tests, this model focuses on predicting survival prediction
based on gene expression in the tumor, presumably before or during drug therapy.” 
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expression involved in developing these classifiers from gene expression data (e.g., van't Veer et












and tumor response to certain therapies (Duan  , 2003; Glinsky  , 2005; Hatzis  , 2011;et al. et al. et al.














Page 17 of 25






Comment 5. Based on the previous review, the authors include context with other predictions of
the METABRIC data in the response to the reviewers. This must also be included in the Conclusion

























 03 October 2016Reviewer Report
https://doi.org/10.5256/f1000research.10141.r16345








Page 18 of 25





























I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 13 Jan 2017
, University of Western Ontario, London, CanadaPeter Rogan
Comment 1:What are the values of parameters for SVM and RF classifiers and the methods for








Comment 2: The development and evaluation of models for patient data are not clear. Whether the
models were trained using partial data from METABRIC or only leave-one-out cross-validation was
applied? If cross-validation is the case, then what is the model offered at the online server because
there will be more than one models created, and whether the cross-validation is involved in the
feature selection process that often leads to an overestimation of the performance. For the case of
Page 19 of 25
F1000Research 2017, 5:2124 Last updated: 03 MAR 2020
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there will be more than one models created, and whether the cross-validation is involved in the
feature selection process that often leads to an overestimation of the performance. For the case of
training on partial data, both training and test performance are essential information for evaluating
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